Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cantargia AB ( (SE:CANTA) ) has provided an announcement.
Cantargia AB’s annual general meeting approved the 2025 financial statements, decided to retain all earnings without distributing a dividend, and discharged the board and CEOs from liability, while confirming a five-member board with Magnus Persson re-elected as chairman. Shareholders also set board and committee remuneration, reappointed Öhrlings PricewaterhouseCoopers as auditor, and approved the remuneration report and guidelines aimed at keeping executive pay competitive.
The meeting adopted a long-term variable share-based incentive scheme for senior executives and key personnel, capped at SEK 2.7 million, and a substantial employee stock option program of up to 4.1 million options supported by a directed warrant issue, strengthening equity-based incentives across the workforce. In addition, the board received a mandate to issue new shares, warrants, or convertibles up to 10 percent of current share capital, providing financial flexibility for future capital raising or strategic initiatives that could support Cantargia’s continued development in oncology and inflammatory disease therapies.
The most recent analyst rating on (SE:CANTA) stock is a Buy with a SEK14.00 price target. To see the full list of analyst forecasts on Cantargia AB stock, see the SE:CANTA Stock Forecast page.
More about Cantargia AB
Cantargia AB is a Swedish biotechnology company developing antibody-based treatments for life-threatening diseases, built around a platform targeting the IL1RAP protein implicated in various cancers and inflammatory conditions. Its lead oncology candidate nadunolimab (CAN04) is in clinical studies with chemotherapy for pancreatic and non-small cell lung cancer, while a second program, CAN10 for autoimmune and inflammatory diseases, was acquired by Otsuka Pharmaceutical in 2025; the company is listed on Nasdaq Stockholm under the ticker CANTA.
Average Trading Volume: 1,625,536
Technical Sentiment Signal: Sell
Current Market Cap: SEK863.7M
For an in-depth examination of CANTA stock, go to TipRanks’ Overview page.